Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons
Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons: A Randomized Clinical Trial
Approximately 5.3 million people live with a long-term disability resulting from a traumatic brain injury (TBI) and between 5-8% of those older than 60 suffer from Alzheimer's disease or other forms of dementia (ADRD). Consequences of these conditions can result in dramatic and persistent changes in functioning, impacting not only the patients, but also loved ones who become informal support persons. Many existing services help the family in the moment, but do not address long-term wellness. Thus, the purpose of this research study is to compare the effect of two different types of group wellness treatments for individuals with chronic mild TBI, moderate to severe TBI, and ADRD and their support persons.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The study will involve three sites, with a different clinical population targeted at each site. Kessler Foundation will serve as the Coordinating Center and will enroll individuals with moderate/severe TBI. Indiana University and University of Michigan will serve as partnering sites and will enroll individuals with chronic mild TBI and ADRD respectively. The research protocols at each site will be unique to the patient population, but harmonized through unified project goals: 1) to evaluate the efficacy of two different online group wellness treatments designed to improve self-efficacy and quality of life, and 2) to determine whether patient neurobehavioral functioning moderates the relationship between treatment outcomes and burden in caregivers, and 3) to determine the neural, behavioral, and blood biomarkers that best predict treatment efficacy. It is expected that findings generated from this study will lead to improved holistic approaches for brain injury and dementia systems of care.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Diana Maloku, B.S.
- Phone Number: 973-324-8393
- Email: dmaloku@kesslerfoundation.org
Study Locations
-
-
New Jersey
-
East Hanover, New Jersey, United States, 07936
- Recruiting
- Kessler Foundation
-
Contact:
- Matthew Weiner
- Phone Number: 973-324-3515
- Email: mweiner@kesslerfoundation.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For individuals with moderate/severe TBI:
Inclusion Criteria:
- age 18-70
- at least 4 months post injury
- can read and speak English fluently
- has a support person who is willing to participate in the study
Exclusion Criteria:
- has had a prior stroke or neurological disease other than TBI
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
For individuals with chronic mild TBI:
Inclusion Criteria:
- age 18-70
- at least 3 months post-injury
- can read and speak English fluently
- has a support person who is willing to participate in the study
Exclusion Criteria:
- has had a prior stroke or neurological disease other than mild TBI
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
For Individuals with Alzheimer's Disease Related Dementias (ADRD)
Inclusion Criteria:
- age 65 and older
- at least one-year post-diagnosis
- can read and speak English fluently
- has a support person who is willing to participate in this study
Exclusion Criteria:
- has had a prior stroke or neurological disease other than ADRD
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
For Support Persons:
Inclusion Criteria:
- is the support person of an individual with moderate/severe TBI, chronic mild TBI or ADRD who is willing to participate in the study
- can read and speak English fluently
Exclusion Criteria:
- has a significant neurological history (e.g. stroke or multiple sclerosis)
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group Wellness Class 1
|
Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours. |
|
Active Comparator: Group Wellness Class 2
|
Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on Self-Efficacy Questionnaire (SEQ)
Time Frame: 12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
self-report instrument that assesses an individual's and support person's self-efficacy as it relates to their ability to manage the effects of the neurologic conditions on their daily functioning |
12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
|
Change on Satisfaction with Life Scale (SWLS)
Time Frame: 12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
self-report measure that examines life satisfaction component of subjective well-being and quality of life |
12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Wounds and Injuries
- Neurocognitive Disorders
- Tauopathies
- Neurodegenerative Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Brain Injuries
- Brain Injuries, Traumatic
- Alzheimer Disease
- Brain Concussion
- Dementia
Other Study ID Numbers
Other Study ID Numbers
- R-1157-21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.